Clinical trials of antibody therapy.
Much of the 25 years since Kohler and Milstein first described making monoclonal antibodies (mAbs) has been spent trying to develop these reagents to treat human disease. Until recently, progress has been frustratingly slow and by 1994 only one mAb, anti-CD3 (OKT3), had been licensed for clinical use. In the past five years, however, the situation has changed dramatically, with numerous mAbs now showing clinical potential, and a further seven approved for human treatment. Furthermore, all indications are that this upward trend will continue, with a quarter of all new biological products currently undergoing clinical development being antibody based.
Glennie
M J
MJ
Tenovus Research Laboratory, The Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK SO16 6YD. mjg@soton.ac.uk
Johnson
P W
PW
D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D015398:Signal Transduction / Q000276:immunology
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D007141:Immunoglobulin Fc Fragments; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins